BeiGene, Ltd. (ONC)vsPTC Therapeutics Inc (PTCT)
ONC
BeiGene, Ltd.
$283.45
+2.81%
HEALTHCARE · Cap: $31.62B
PTCT
PTC Therapeutics Inc
$66.75
+3.42%
HEALTHCARE · Cap: $5.34B
Smart Verdict
WallStSmart Research — data-driven comparison
BeiGene, Ltd. generates 209% more annual revenue ($5.34B vs $1.73B). PTCT leads profitability with a 39.4% profit margin vs 5.4%. PTCT trades at a lower P/E of 7.5x. PTCT earns a higher WallStSmart Score of 45/100 (D).
ONC
Hold42
out of 100
Grade: D
PTCT
Hold45
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-1983.5%
Fair Value
$16.86
Current Price
$283.45
$266.59 premium
Margin of Safety
-21.6%
Fair Value
$58.34
Current Price
$66.75
$8.41 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 32.8% year-over-year
Conservative balance sheet, low leverage
Attractively priced relative to earnings
Keeps 39 of every $100 in revenue as profit
Growing faster than its price suggests
Areas to Watch
0.0% earnings growth
ROE of 7.5% — below average capital efficiency
5.4% margin — thin
Premium valuation, high expectations priced in
0.0% earnings growth
ROE of -77.4% — below average capital efficiency
Revenue declined 22.7%
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : ONC
The strongest argument for ONC centers on Revenue Growth, Debt/Equity. Revenue growth of 32.8% demonstrates continued momentum.
Bull Case : PTCT
The strongest argument for PTCT centers on P/E Ratio, Profit Margin, PEG Ratio. Profitability is solid with margins at 39.4% and operating margin at -49.6%. PEG of 0.81 suggests the stock is reasonably priced for its growth.
Bear Case : ONC
The primary concerns for ONC are EPS Growth, Return on Equity, Profit Margin. A P/E of 111.0x leaves little room for execution misses.
Bear Case : PTCT
The primary concerns for PTCT are EPS Growth, Return on Equity, Revenue Growth.
Key Dynamics to Monitor
ONC profiles as a hypergrowth stock while PTCT is a declining play — different risk/reward profiles.
PTCT carries more volatility with a beta of 0.56 — expect wider price swings.
ONC is growing revenue faster at 32.8% — sustainability is the question.
ONC generates stronger free cash flow (131M), providing more financial flexibility.
Bottom Line
PTCT scores higher overall (45/100 vs 42/100), backed by strong 39.4% margins. Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
BeiGene, Ltd.
HEALTHCARE · BIOTECHNOLOGY · USA
BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company is headquartered in Camana Bay, the Cayman Islands.
Visit Website →PTC Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for patients with rare disorders. The company is headquartered in South Plainfield, New Jersey.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?